ADMA Biologics

ADMA

Market cap $1.79B

ADMA Biologics (ADMA) faces IVIG market headwinds, flat Q1 revenue, and reduced 2026 guidance, leading to a >50% YTD share price decline. ASCENIV's differentiated profile drove 28% YoY revenue growth and record utilization, partially offsetting BIVIGAM's 54% decline amid IVIG pricing pressure. Gross margin expanded to 71%, adjusted EBITDA rose 24% YoY, and strong cash generation supports resilience despite market disruption.

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.

Did ADMA Biologics Mislead Investors about Alleged Channel Stuffing? BFA Law Notifies Investors with Losses of the Pending Securities Fraud Investigation

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

ADMA faces IG pricing pressure and reduced 2026 guidance, but Asceniv demand remains strong amid resilient patient utilization.

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.

AMTB, ADMA and AHEXY have been added to the Zacks Rank #5 (Strong Sell) List on May 26, 2026.

NEW YORK, May 25, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.